We are dedicated to enhancing drug discovery and development of novel cancer therapies through democratizing access to Causal AI across the life sciences industry.
Enabling target discovery groups to rapidly interrogate and extract meaningful biological insights from public and private research literature and omics datasets, and perform Causal AI on the hypothesized mechanisms. The resulting outputs provide unique quantification and simulation of the mechanisms, accelerating drug discovery programs.
Based across Europe and the US, we are a multidisciplinary team of biologists, data scientists, and industry experts with deep knowledge of and leadership experience with cancer-related AI technologies.
We are the first commercial providers of a Causal AI technology that is capable of in silico exploration of biological pathway and mechanisms. For this, we have built a first-of-a-kind software platform, ALaSCA.
To date, ALaSCA has been used to discover and simulate the effect of drivers in a number of disease and treatment types - including Glioblastoma, Alzheimer's Disease, Chronic Liver Disease, Rare Kidney Disease, Diabetes, AMR, and Bioactives.
Download a summary of scientific questions we regularly work on:
ALaSCA has enabled us to computationally explore and quantitatively assess multiple rare diseases (including ADPKD) in which to further exploit our underlying technology platform. This has allowed us to rapidly prioritise resources to those areas where our compounds are likely to have the most beneficial effect. ALaSCA has saved us potentially several months of time and wet lab experiments.
Neil Wilkie, CEO, Mironid Ltd